Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: Defining the right patient population

Pranita D. Tamma, Maria Virginia Villegas

Research output: Contribution to journalComment/debatepeer-review

Abstract

In a multicenter, multinational observational study that included neutropenic patients with bloodstream infections by extended-spectrum-β-lactamase-producing species, Gudiol et al. (Antimicrob. Agents Chemother. 61:e00164-17, 2017, https://doi.org/10.1128/AAC.00164-17) demonstrated that β-lactam/β-lactamase inhibitors are effective treatment options. A review of this work, however, reminds us that some lingering questions remain for specific high-risk subgroups.

Original languageEnglish (US)
Article numbere01094
JournalAntimicrobial agents and chemotherapy
Volume61
Issue number8
DOIs
StatePublished - Aug 2017

Keywords

  • ESBL
  • Gram negative
  • MDRGN
  • Meropenem
  • Piperacillin-tazobactam

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: Defining the right patient population'. Together they form a unique fingerprint.

Cite this